Within TME, VSIG4 is specifically expressed in TAMs [2], and this expression has been shown to be associated with a poor prognosis in multiple tumor types, including non-small cell lung cancer, gastric cancer, multiple myeloma, ovarian cancer, and glioma, suggesting an important broad functional role at the tumor–immune interface [3,4,5]. Here, VSIG4 is linked to non-small cell lung carcinoma.